These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38383218)

  • 41. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Complexity of immune responses to AAV transgene products - Example of factor IX.
    Herzog RW
    Cell Immunol; 2019 Aug; 342():103658. PubMed ID: 28645365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The gene therapy journey for hemophilia: are we there yet?
    High KA
    Hematology Am Soc Hematol Educ Program; 2012; 2012():375-81. PubMed ID: 23233607
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The gene therapy journey for hemophilia: are we there yet?
    High KA
    Blood; 2012 Nov; 120(23):4482-7. PubMed ID: 22829631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene therapy for hemophilia.
    Nathwani AC
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):569-578. PubMed ID: 36485127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.
    Buchlis G; Podsakoff GM; Radu A; Hawk SM; Flake AW; Mingozzi F; High KA
    Blood; 2012 Mar; 119(13):3038-41. PubMed ID: 22271447
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.
    Mingozzi F; Chen Y; Murphy SL; Edmonson SC; Tai A; Price SD; Metzger ME; Zhou S; Wright JF; Donahue RE; Dunbar CE; High KA
    Mol Ther; 2012 Jul; 20(7):1410-6. PubMed ID: 22565846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
    Samelson-Jones BJ; Finn JD; George LA; Camire RM; Arruda VR
    JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
    Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
    Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques.
    Mattar CN; Nathwani AC; Waddington SN; Dighe N; Kaeppel C; Nowrouzi A; Mcintosh J; Johana NB; Ogden B; Fisk NM; Davidoff AM; David A; Peebles D; Valentine MB; Appelt JU; von Kalle C; Schmidt M; Biswas A; Choolani M; Chan JK
    Mol Ther; 2011 Nov; 19(11):1950-60. PubMed ID: 21629224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. WFH State-of-the-art paper 2020: In vivo lentiviral vector gene therapy for haemophilia.
    Cantore A; Naldini L
    Haemophilia; 2021 Feb; 27 Suppl 3(Suppl 3):122-125. PubMed ID: 32537776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy.
    Vandendriessche T; Thorrez L; Acosta-Sanchez A; Petrus I; Wang L; Ma L; DE Waele L; Iwasaki Y; Gillijns V; Wilson JM; Collen D; Chuah MK
    J Thromb Haemost; 2007 Jan; 5(1):16-24. PubMed ID: 17002653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
    Hasbrouck NC; High KA
    Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.
    Sabatino DE; Mackenzie TC; Peranteau W; Edmonson S; Campagnoli C; Liu YL; Flake AW; High KA
    Mol Ther; 2007 Sep; 15(9):1677-85. PubMed ID: 17565352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
    Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
    Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.
    Wang L; Calcedo R; Nichols TC; Bellinger DA; Dillow A; Verma IM; Wilson JM
    Blood; 2005 Apr; 105(8):3079-86. PubMed ID: 15637142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.
    Jiang H; Pierce GF; Ozelo MC; de Paula EV; Vargas JA; Smith P; Sommer J; Luk A; Manno CS; High KA; Arruda VR
    Mol Ther; 2006 Sep; 14(3):452-5. PubMed ID: 16822719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.